[22] What this means for you Current workarounds: Coverage for type 2 diabetes (Mounjaro) Coverage for obstructive sleep apnea (OSA) Zepbound is FDA-approved for OSA in adults with obesity Medicare GLP-1 Bridge (July 1, 2026): $50/month copay for eligible beneficiaries BMI 35 , or BMI 30 with heart failure, uncontrolled hypertension, or CKD stage 3a+ Covers Zepbound KwikPen, Wegovy, and Foundayo The BALANCE Model continues in Medicare Part D starting January 2027
In 2023, 25% of self-funded health plans incorporate weight loss treatments, a figure anticipated to jump to 43% in 2024
Semaglutide works by mimicking hormones that regulate appetite, helping you feel full longer and reduce calorie intake
Your brain's hunger centers become active again, cravings intensify, and portion control becomes difficult without the medication's support
They found that at the highest dosage of 4.8 mg survodutide weekly, study participants lost 14.9% of their body weight in comparison with a placebo group (2.8% weight loss) [122]
